Boditech Med Unveils Next-Generation Diabetes Diagnostics at EASD 2025

-  HbA1c, insulin, and C-peptide testing available on a single platform within 12 minutes

-  A paradigm shift in POC diabetes diagnostics: assessing underlying causes, not just blood sugar levels

-  Sustained growth trajectory fueling accelerated global expansion

Seoul, South Korea – September 19, 2025 – Boditech Med, a leading provider of point-of-care diagnostics, showcased its groundbreaking diabetes diagnostic solutions at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025), held in Vienna, Austria from September 16–19. The event attracted over 15,000 diabetes experts, clinicians, and industry professionals from around the world.

At its booth, Boditech Med highlighted the unique value of its platform, which enables rapid measurement of HbA1c, insulin, and C-peptide directly from whole blood in as little as 12 minutes. Traditionally, insulin and C-peptide testing has required large laboratory-based systems with limited accessibility. Boditech Med’s solution allows clinicians to simultaneously evaluate insulin resistance through indices such as HOMA-IR, as well as assess β-cell function and insulin secretion capacity. This represents a shift beyond standard blood glucose monitoring—offering a more comprehensive approach to diagnosing and managing diabetes.

The company reported strong engagement during the exhibition, with approximately 300 endocrinologists, laboratory directors, and diabetes specialists from over 30 countries visiting its booth. Particular interest was shown in the insulin/C-peptide panel and insulin resistance evaluation solution, underscoring market demand for rapid point-of-care testing. The demonstration further enhanced Boditech Med’s brand recognition among global diabetes experts.

Boditech Med’s diabetes product portfolio has shown sustained high growth. Revenue from diabetes-related products grew from KRW 4.4 billion in 2019 to over KRW 13 billion in 2024, recording a compound annual growth rate (CAGR) of more than 24%. The company expects growth of over 25% in 2025. While HbA1c products have historically led sales, the company anticipates significant contributions from insulin and C-peptide diagnostics going f orward, given their clinical utility in reflecting endogenous insulin secretion and β-cell function.

Eui-yeol Choi, CEO of Boditech Med, stated:

“EASD 2025 provided an important opportunity to introduce the new value of ‘diabetes diagnostics beyond glucose’ to a global audience. We will continue to deliver innovative solutions that provide tangible benefits to clinicians and patients, while accelerating our global expansion in the diabetes diagnostics market.”